Internal medicine

Hepatocellular carcinoma

VEGF receptors

Oncology

Vascular endothelial growth factor

Carcinoma

Sorafenib

Cancer research

Medicine

New England Journal of Medicine

No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma.

Sorafenib in Advanced Hepatocellular Carcinoma